A Phase 3 interventional study of Masitinib and Placebo in Alzheimer Disease, sponsored by AB Science. Completed at 6 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by AB Science · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Alzheimer Disease with a site in Bulgaria — 8 open to participants now, 8 under way, 5 of them phase 3. Alzheimer Disease · Bulgaria.
Among the 39 studies in Alzheimer Disease with a site in Bulgaria, this one is the 15th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2012, is one of 26 in phase 3, and was the 15th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →8 of the 39 studies in Alzheimer Disease with a site in Bulgaria are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Bulgaria, United States, Argentina and 23 more countries
Ages 55–90
MapLight Therapeutics · Sites in Bulgaria, United States, Argentina and 12 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in Bulgaria, United States, Argentina and 12 more countries
Ages 55–90
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Bulgaria, United States, Argentina and 22 more countries
Ages 55–90
Intra-Cellular Therapies, Inc. · Sites in Bulgaria, United States, Croatia and 7 more countries
Ages 55+
A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 721 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 589 across the 38 interventional studies, 450 across the 1 observational. Of the 31 that completed or were terminated, 17 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 39 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Alzheimer Disease with a site in Bulgaria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 39 studies in Alzheimer Disease with a site in Bulgaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.
Actual standard treatment for mild to moderately severe Alzheimer's dementia includes acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and a NMDA receptor antagonist (memantine for moderate to severe Alzheimer's disease). These medications have shown to have an effect on some cognitive and non cognitive symptoms of the pathology. However, their efficacy remains limited and may decrease with time. There is an unmet medical need in this pathology. Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes, as well as possibly disruption of the Aβ signaling cascade via inhibition of the Fyn signaling pathway. This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study of oral masitinib. The objective of this study is to compare the efficacy and safety of masitinib at various doses versus matched placebo in the treatment of patients with mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine. Approximately 675 patients will be randomized into 5 treatment groups. The co-primary outcome measures are the Alzheimer's Disease Cooperative Study Activities of Daily Living score (ADCS-ADL), and Alzheimer's Disease Assessment Scale-Cognitive Subscale score (ADAS-Cog) after 24 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
Drug: Masitinib · Drug: Standard of care
Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
Drug: Masitinib · Drug: Standard of care
Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
Drug: Masitinib · Drug: Standard of care
Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
Drug: Placebo · Drug: Standard of care
Participants receive fixed dose placebo, given orally twice daily
Drug: Placebo · Drug: Standard of care
Also known as: AB1010
Also known as: Placebo Oral Tablet
stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
ADCS-ADL
Change in the Alzheimer's Disease Cooperative Study Activities of Daily Living score (ADCS-ADL).
Time frame: 24 weeks
ADAS-Cog
Change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale score (ADAS-Cog).
Time frame: 24 weeks
MMSE
Change in Mini Mental State Examination (MMSE)
Time frame: 24 weeks
CIBIC-plus
Clinician's Interview Based Impression of Change-plus (CIBIC-plus)
Time frame: 24 weeks
Ran from Jan 2012 to primary completion in Dec 2020, 107 months.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 107 months is above that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib